2026-04-17T02:33:08Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1649432025-12-05T16:26:32Zcom_2072_1057col_2072_478917col_2072_478921

urn:hdl:2445/164943 Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response Iglesias, Pablo Ribero, Simone Barreiro Capurro, Alicia Podlipnik, Sebastian Carrera Álvarez, Cristina Malvehy, J. (Josep) Puig i Sardà, Susana Càncer de pell Vitiligen Melanoma Skin cancer Vitiligo Melanoma Talimogene laherparepvec (T-VEC) (Imlygic, Amgen) is the first oncolytic virus approved for use in therapy for metastatic melanoma. T-VEC provides a treatment option for patients with limited metastatic disease. T-VEC is a genetically modified, live, attenuated herpes simplex virus type 1 designed to replicate in tumour cells and promote an enhanced anti-tumour response (1) T-VEC is administered by injection into cutaneous, subcutaneous or nodal lesions, which are visible and/or palpable and/ or visualized by ultrasonography (2). Other local management options have been used to control metastatic disease in stage IIIB, but almost all have shown only a local effect and rapid disease relapse (3, 4). With T-VEC, responses occurred in injected and uninjected lesions, including a greater than 50% decrease in size in 15% of uninjected visceral lesions. The appearance of vitiligo has been described as an adverse event after administration of immune checkpoint inhibitors (5, 6). It has been reported as a marker of activity of the drug and long-term results, inducing clinicians to use it as a predictor of drug response (7). A T-VEC phase II study has reported 85% adverse events, all of which were grade 1 or 2. The appearance of vitiligo has been described in 3 patients out of 50 (8), although no details regarding duration and appearance have been reported. 2020-06-09T11:38:34Z 2020-06-09T11:38:34Z 2019-02-01 2020-06-09T11:38:34Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Reproducció del document publicat a: https://doi.org/10.2340/00015555-3061 Acta Dermato-Venereologica, 2019, vol. 99, num. 2, p. 232-233 https://doi.org/10.2340/00015555-3061 (c) Iglesias, Pablo et al., 2019 info:eu-repo/semantics/openAccess Society for the Publication of Acta Dermato-Venereologica Articles publicats en revistes (Medicina)